

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7934151

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADC THERAPEUTICS SA	04/26/2023
RECEIVING PARTY DATA	
Name:	MEDIMMUNE LIMITED
Street Address:	1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS
City:	CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB2 0AA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	11596696
CORRESPONDENCE DATA	
Fax Number:	(703)712-8525
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7037128531
Email:	bcaraway@medlerferro.com, docketing@medlerferro.com
Correspondent Name:	MEDLER FERRO WOODHOUSE & MILLS PLLC
Address Line 1:	8201 GREENSBORO DRIVE, SUITE 1060
Address Line 4:	MCLEAN, VIRGINIA 22102
ATTORNEY DOCKET NUMBER:	0233-0006US1
NAME OF SUBMITTER:	NEIL P. SHULL
SIGNATURE:	/Neil P. Shull, #60238/
DATE SIGNED:	05/03/2023
Total Attachments: 2	
source=0233-0006US1_Assignment#page1.tif	
source=0233-0006US1_Assignment#page2.tif	

ASSIGNMENT OF SHARES IN US PATENT

WHEREAS,

1) ADC Therapeutics SA

A corporation organized under the laws of Switzerland and having a place of business at Route de la Corniche 3B, Epalinges 1066, Switzerland (hereinafter referred to as the **ASSIGNOR**)

AND WHEREAS

2) MedImmune Limited

A corporation organized under the laws of England and Wales and having a place of business at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (hereinafter referred to as the **ASSIGNEE**)

Are joint applicants in the US Patent set out in Schedule A attached hereto.

ASSIGNEE is desirous of acquiring and ASSIGNOR has agreed to assign all its entire right title and interest in and to said patent and the invention(s) and improvement(s) therein disclosed, for the United States of America, and any Letters Patent which may issue therefor in the United States, so that such shall be granted in the name of ASSIGNEE alone and shall vest in ASSIGNEE solely.


NOW THEREFORE for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the ASSIGNOR does hereby assign, sell, transfer and set over unto the ASSIGNEE absolutely all of its entire right, title and interest in and to said patent and the invention(s) therein disclosed, for the United States of America, and any Letters Patent which may issue therefor in the United States, said ASSIGNEE to have and to hold the interests herein assigned alone, to the full ends of the terms of said Letters Patents, together with all benefit and advantages thereunto belonging or accrued with the intent that any patent or patents granted thereon shall be granted in the name of ASSIGNEE alone and shall vest in ASSIGNEE solely.


And for the consideration aforesaid, ASSIGNOR agrees that ASSIGNOR will, upon request, communicate to said ASSIGNEE or the representatives thereof any facts known to ASSIGNOR respecting the invention(s) of the said United States application, and will, upon request, but without expense to ASSIGNEE, testify in any legal proceedings, sign all lawful papers, make all rightful oaths, and generally do all other and further lawful acts deemed

necessary or expedient by said ASSIGNEE or by counsel for said ASSIGNEE, to assist or enable said ASSIGNEE to obtain and enforce full benefits from the rights and interests herein assigned.

This assignment shall be binding upon the ASSIGNOR's heirs, executors, administrators, successors and/or assigns, and shall inure to the benefit of the heirs, executors, administrators, successors, and/or assigns, as the case may be, of the ASSIGNEE.

The Commissioner of Patents is requested to issue such Letters Patent in accordance with this assignment.


1) Signature: **ADC Therapeutics SA**
Name: NICHOLAS FINNIE
Date: 26th April 2023

2) Signature: **MedImmune Limited**
Name:  **ANDREW COOK**
Date: 03-MAY-2023

SCHEDULE A

US Application Number	US Patent Number	Application Date
16/605,708	11,596,696	20 April 2018